Gene Therapy Has Crossed Into the Sensory Systems. The Hearing-Aid Industry Has Not Noticed.

The FDA approved a gene therapy for hearing loss on Thursday. Behind the milestone, something larger is shifting.

Regeneron Pharmaceuticals won clearance for Otarmeni, a one-time treatment for OTOF-related hearing loss — a rare genetic form of deafness caused by variants in the OTOF gene that prevent the inner ear from transmitting sound signals to the brain. In the pivotal CHORD trial, 80% of participants regained enough hearing to avoid cochlear implantation. Forty-two percent achieved normal hearing, including the ability to hear whispers. The treatment works by delivering a functional copy of the OTOF gene via an adeno-associated virus injected into the cochlea. All structures of the ear are intact in these patients. The gene was not. Regeneron press release

The clinical picture is narrow. OTOF-related hearing loss affects roughly 50 newborns per year in the United States — an ultra-rare population that makes this neither a public health intervention nor a blockbuster revenue opportunity by conventional measures. Regeneron will provide Otarmeni at no cost to eligible patients in the U.S. That is not charity. It is the price of entry into the Trump administration's Most Favored Nation drug pricing framework, which the White House announced the same day alongside Regeneron as its 17th signing company. Regeneron was the last major pharmaceutical holdout. The free drug offer is tied to that deal. Washington Post Reuters

Dr. Eliot Shearer, a pediatric otolaryngologist at Boston Children's Hospital and a CHORD trial investigator, put it plainly: there are over 150 known genetic causes of hearing loss, and thousands of mutations within them. What Otarmeni proves is not just a new drug. It proves the inner ear is reachable, that sensory neurons can be rewired, and that the category of permanent hearing loss is a statement about current medicine, not an immutable fact of biology. New York Times

That distinction matters far beyond the 50 children per year who carry OTOF variants.

The hearing-aid and cochlear-implant industry has built a combined market valued in the tens of billions of dollars on exactly the premise that hearing loss is permanent. Companies like Cochlear Ltd, Sonova, Starkey, and Demant manufacture devices that manage the condition rather than cure it. Their growth strategies, investor presentations, and pipeline decisions all flow from the assumption that patients with sensorineural hearing loss will need technological assistance for life. None of these companies have disclosed gene therapy as a material risk to investors in their public filings, according to a review of recent annual reports and investor communications. If sensory gene therapies can scale beyond ultra-rare monogenic conditions — and the FDA just approved one for quality-of-life sensory deficits rather than a life-threatening disease — that assumption requires revision.

Eli Lilly is developing AK-OTOF, another otoferlin-targeted therapy, with a Phase 1/2 trial expected to conclude in October 2028. Sensorion and Refreshgene Therapeutics have also been studying OTOF-directed approaches. The CHORD trial data, published in the New England Journal of Medicine in October 2025, showed not only clinical benefit but an absence of serious adverse events attributable to the gene therapy itself — only to the surgical procedure required to deliver it. That safety profile matters for the platform argument: if the inner ear can be rewired safely, other sensory deficits may follow. BioSpace

Otarmeni received accelerated approval based on hearing improvements at 24 weeks. Continued approval is contingent on verification of clinical benefit in the confirmatory portion of CHORD. Regeneron's Genetics Center and VelociSuite platform produced the therapy; it is the company's first approved genetic medicine. The Myo15 promoter used to restrict gene expression to hair cells represents a molecular precision that the field has pursued for years. Regeneron press release

The irreversibility barrier — the medical consensus that certain forms of neural damage are simply not repairable — has been eroding across organ systems. Gene therapies have moved from blood disorders to retinal degeneration to muscular dystrophy. The inner ear is now on the other side. What the hearing-aid industry built on the assumption of permanence has a competitor it did not model for.